Jasper Therapeutics to Showcase Innovations at September Events
Jasper Therapeutics, Inc. (NASDAQ: JSPR), a leader in biotechnology, is preparing for a series of investor conferences this September. The company is particularly excited to discuss briquilimab, an innovative antibody therapy designed to treat c-Kit (CD117) driven mast cell diseases, including chronic spontaneous urticaria (CSU) and asthma. Jasper looks forward to sharing its progress and insights during these events.
Key Conference Details
Jasper Therapeutics will take part in three significant investor conferences:
H.C. Wainwright 26th Annual Global Investment Conference
This important event is scheduled for September 9-11, 2024, with Jasper's presentation taking place on September 10 at 3:00 p.m. ET. The format will be a fireside chat, allowing for a more personal interaction with Jasper's leadership team.
2024 Cantor Fitzgerald Healthcare Conference
Following the H.C. Wainwright conference, Jasper will participate in the Cantor Fitzgerald Healthcare Conference from September 17 to 19, 2024. Jasper's presentation is set for September 17 at 2:30 p.m. ET, also in a fireside chat format, ensuring a responsive dialogue with investors in attendance.
TD Cowen Chronic Urticaria Summit
The final event in this series will be the TD Cowen Chronic Urticaria Summit, taking place on September 20, 2024. Jasper will present at noon ET, providing further insights into the promising outcomes from their clinical research.
Accessing Presentations
For those interested in the presentations, live webcasts will be available on Jasper’s Investor Relations site. Additionally, an archived replay will be accessible for a limited time after the live events, ensuring that more people can stay informed about Jasper's innovations.
About Jasper Therapeutics
Jasper is a clinical-stage biotechnology company dedicated to transforming treatment options for patients with chronic mast and stem cell diseases through briquilimab. This monoclonal antibody specifically targets c-Kit (CD117) and plays a crucial role for patients suffering from conditions such as chronic urticaria, asthma, and myelodysplastic syndromes (MDS). Briquilimab has shown safety and efficacy in clinical trials involving over 145 participants. Moreover, it functions as a conditioning agent for stem cell transplants, offering hope to individuals facing rare diseases.
Company’s Commitment to Innovation
Jasper is committed to advancing clinical development, consistently revealing data that underscores the advantages of briquilimab as it progresses through trials. Its potential to improve patient outcomes for conditions like acute myeloid leukemia and severe combined immunodeficiency is significant. Ongoing research is vital for raising the standards of care in these challenging medical fields.
Frequently Asked Questions
1. What is briquilimab?
Briquilimab is a monoclonal antibody developed by Jasper Therapeutics that targets c-Kit (CD117) to treat mast cell diseases.
2. How effective is briquilimab in clinical trials?
Briquilimab has demonstrated a promising safety and efficacy profile in over 145 trial participants, addressing various complex conditions.
3. When and where will Jasper’s presentations occur?
Jasper will present at three conferences in September 2024, with key details outlined in the article above.
4. Can I watch the presentations online?
Yes, live webcasts of the presentations will be available on Jasper’s Investor Relations website, along with archived replays after the events.
5. Who should I contact for more information?
For investor inquiries, you can contact Joyce Allaire at LifeSci Advisors or Alex Gray at Jasper Therapeutics, both of whom are mentioned in the original article.